Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation
Impact of thrombophilic gene mutations and graft-versus-host disease on thromboembolic complications after allogeneic hematopoietic stem-cell transplantation
复制标题
DOI：
10.1097/01.tp.0000136988.38919.fb
复制
发表时间：
2004-09-27
期刊：
影响因子：
6.2
通讯作者：
Pinhusch, R
中科院分区：
文献类型：
--
作者：
Pihusch, M;Lohse, P;Pinhusch, R
背景异基因造血干细胞移植（HSCT）患者的止血事件增加了该队列的发病率和死亡率。关于移植物抗宿主病（GvHD）或血栓形成基因突变/多态性对这些并发症的影响知之甚少。前瞻性评估89例异基因干细胞受体及其供体是否存在凝血因子V G1691 A突变、凝血酶原G20210 A突变、5，10-亚甲基四氢叶酸还原酶（MTHFR）C677 T突变、糖蛋白伊利亚pI（a1/a2）多态性、纤维蛋白原β链455 G/A多态性、纤溶酶原激活物抑制剂-1-675 4G/5G多态性和血管紧张素转换酶内含子16 I/D多态性。这些突变/多态性和GvHD参数与移植后止血和毒性并发症相关。并与128例健康对照组进行比较。派-1 4G/4G多态性使HSCT后导管血栓形成的风险增加5.7倍（32.2% vs. 71.4%，P
Background. Hemostatic events in patients undergoing allogeneic hematopoietic stem-cell transplantation (HSCT) increase the morbidity and mortality in this cohort. Little is known about the impact of graft-versus-host disease (GvHD) or of thrombophilic gene mutations/polymorphisms on these complications.Study Design. Eighty-nine allogeneic stem-cell recipients and their donors were evaluated prospectively for the presence of the factor V G1691A mutation, the prothrombin G20210A mutation, the 5,10-methylenetetrahydrofolate-reductase (MTHFR) C677T mutation, the glycoprotein Ilia pI(a1/a2) polymorphism, the fibrinogen-beta-chain 455G/A polymorphism, the plasminogen activator inhibitor-1 -675 4G/5G polymorphism, and the angiotensin-converting enzyme intron 16 I/D polymorphism. These mutations/polymorphisms and GvHD parameters were correlated to hemostatic and toxic complications after transplantation. The data were compared with those of 128 healthy controls.Results. The PAI-1 4G/4G polymorphism increases the risk for catheter thrombosis after HSCT 5.7-fold (32.2% vs. 71.4%, P